Drug Profile
Research programme: cancer therapeutics - AbbVie/Lurie Cancer Center
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator AbbVie; Lurie Cancer Center; Northeastern University
- Developer AbbVie; Lurie Cancer Center
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 05 Dec 2016 AbbVie and Lurie Cancer Center sign a five-year collaboration agreement for the discovery and development of therapies for Cancer